Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

MoodMoney Dec. 25 at 12:37 PM

$BLRX Volatility reflects tension between long‑term potential and near‑term uncertainty. Commercial adoption must become steadier to neutralize skepticism around sustainability. Missed checkpoints may compound into higher capital costs. Risk remains manageable if management converts plans into consistent outputs.

0 · Reply

gargoyl Dec. 21 at 8:44 PM

$BLRX long the 🦋 DD 👇🏼 Catalysts 🐈‍⬛ …..🐈 …. 👀 ( Revenue/ Milestones/ Data ) - Gloria Bio partner - Arymid partner / Gamida Cell - Tetragon Biosciences Ltd. / Hemispherian AS - PDAC , SCD, MM , Tumors, APHEXDA/ Aphreses, glioblastoma and other cancers, GLIX1 - Columbia University - Washington University - St. Jude’s Children’s Research Hospital - Regeneron $REGN - GenFleet Cash on hand ✅ Runaway 2027 Low float 13 M market 🧢 cap ( under valued) Low expense burn - Captain 🧑‍✈️ Phil Target 🎯 10x $XBI

0 · Reply

UgoGreg Dec. 20 at 10:52 AM

$BLRX https://youtu.be/ygBN8MilTyc

0 · Reply

Azlvr Dec. 19 at 6:21 PM

$BLRX Review Alejos here. 🫣 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

TwongStocks Dec. 17 at 6:06 PM

$BLRX Gloria updated the status of their SCM trial in China. Status changed to 'RECRUITING' https://clinicaltrials.gov/study/NCT06514508 60 patients estimated. Primary completion Dec 2026. Study completion May 2027. In the past several earnings filings, BLRX disclosed that Gloria was behind schedule with this trial. The trial status change to 'RECRUITING' suggests that Gloria may finally be back on track. BLRX will receive an undisclosed milestone payment from Gloria after marketing approval of APHEXDA for SCM in mainland China (milestone 6.2.3 in the screenshot).

0 · Reply

gargoyl Dec. 17 at 5:02 PM

$BLRX time buy , ready run 🏃‍♂️!!

0 · Reply

gargoyl Dec. 17 at 2:51 PM

$VSTM watch the juxtaposition of these two stocks $BLRX

0 · Reply

tankwfwf Dec. 17 at 12:40 AM

$BLRX Phil keeps rocking the posters, but money is what they will need. Gloria has done nothing the agreement calls for and an offering is coming down the chute. All the while Phil keeps being paid 1,000,000 dollars of your money. The SOB already got mine......to basically do nothing....

0 · Reply

frontiere Dec. 16 at 8:50 PM

$BLRX BioLineRx ref=$3.03 — Long starter size — love the informed poster below 👇 well summarized across their posts. Multiple potential PRs. 👍 own GLIX1 Ph1/2a in Glioblastoma to start in 1Q 2026. 👍REGN combo w BLRX Ph2 in PDAC (historically tough to succeed in tho) prespecified interim futility in 2026. 👍Cash=$23.8m run rate (2025-12-31 est) on sh outst=$4.3m so <$5.5 cash per sh — neg EV, runway into 2027 (very reasonable burn=$1.6m per Qtr). 👍 Overhead, latest ATM raise in 3Q by HCW was at ~$6.5 per sh, + 1.25m wrt EP=$8.00 owned by Intracoastal from the 2025-01-06 raise 👍👍— ie beautiful ample safety margin for a swing from today’s prices. Israel biotech. Lindy chart. New Dec 2025 deck https://ir.biolinerx.com/static-files/f1fbb06b-cb0e-4902-b166-f780a049ba38

1 · Reply

SwingAlpha476 Dec. 16 at 7:58 PM

$BLRX M⁣a‌i‍n⁣z⁣ Bi‌o⁠m⁠e⁤d⁤ ⁢the m‍om⁤e⁣n⁤t‌ ⁤t⁠h‌i⁣s ⁠b⁤e‍c⁠o⁢m⁣e⁢s w⁤i⁣d⁢e‌l⁢y⁣ ‌un⁤d⁠er‌st⁢o⁠o⁢d⁣ ‍a⁠s⁤ a serious US scale program, liquidity can vanish on the offer side because the float is only 8.51M shares, you do not need a huge fund to create a squeeze like move, you just need steady demand, and steady demand is what big study headlines attract, PT 14 is +1,328.57% 🔥

0 · Reply

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

Nov 24, 2025, 7:00 AM EST - 4 weeks ago

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 18, 2025, 7:00 AM EST - 5 weeks ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Nov 17, 2025, 7:00 AM EST - 5 weeks ago

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Sep 29, 2025, 3:27 PM EDT - 3 months ago

BioLineRx Ltd. - Special Call

Sep 29, 2025, 7:00 AM EDT - 3 months ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Aug 14, 2025, 10:44 AM EDT - 4 months ago

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 4 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 5 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

May 30, 2025, 1:58 PM EDT - 7 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 7:00 AM EDT - 7 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 12:55 PM EDT - 7 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 7:00 AM EDT - 7 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025, 7:00 AM EDT - 7 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mar 31, 2025, 10:52 AM EDT - 9 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 9 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:00 AM EDT - 9 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 1 year ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 1 year ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 2:01 PM EST - 1 year ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 8:57 AM EST - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 10:58 AM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 1 year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 2 years ago

BioLineRx: Still A Buy, With Some Questions

MoodMoney Dec. 25 at 12:37 PM

0 · Reply

gargoyl Dec. 21 at 8:44 PM

0 · Reply

UgoGreg Dec. 20 at 10:52 AM

$BLRX https://youtu.be/ygBN8MilTyc

0 · Reply

Azlvr Dec. 19 at 6:21 PM

$BLRX Review Alejos here. 🫣 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

TwongStocks Dec. 17 at 6:06 PM

0 · Reply

gargoyl Dec. 17 at 5:02 PM

$BLRX time buy , ready run 🏃‍♂️!!

0 · Reply

gargoyl Dec. 17 at 2:51 PM

$VSTM watch the juxtaposition of these two stocks $BLRX

0 · Reply

tankwfwf Dec. 17 at 12:40 AM

0 · Reply

frontiere Dec. 16 at 8:50 PM

1 · Reply

SwingAlpha476 Dec. 16 at 7:58 PM

0 · Reply

DiaJay Dec. 16 at 3:59 PM

$BLRX Sad deal here. Another year passes with this company doing nothing of value for shareholders.

0 · Reply

gargoyl Dec. 5 at 5:29 AM

$BLRX I’ll just nonchalantly (never wrote the word down before) put this H👂

0 · Reply

Love_To_Learn Dec. 4 at 1:07 PM

hmmmmmmm maybe blrx can b of service for the next week and their movement yes $BLRX need your wedge as well to merge with capr wedge from years ago work that 36-40 pt later and 2.56 for markets !

0 · Reply

Raspring81 Dec. 3 at 9:36 PM

$BLRX Israeli scam stock

0 · Reply

tankwfwf Dec. 2 at 11:15 PM

$BLRX what happened to Stealing your thunder and imabean. Let us know how you guys knew when to quit pumping and got out. Shame you didn't let us into how you knew Phil and aphexda were just pie in the sky. You fellows pulled out as soon as the drug was approved. Stealing your thunder did the same smoke and mirrors with dare bio.

0 · Reply

Flowjob Dec. 1 at 5:30 PM

$BLRX no mention about the SCD data in the recent ER lol

1 · Reply

aletz Nov. 27 at 7:11 PM

$BLRX https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ On this week's AI scanner result

0 · Reply

ZacksSCR Nov. 25 at 8:10 PM

$BLRX: Stem Cell Mobilization Presentation at ASH https://buff.ly/l1XSHhT

0 · Reply

gargoyl Nov. 25 at 6:20 PM

$BLRX Don’t try figuring it out, just enjoy the journey.. $XBI Long the 🦋

0 · Reply

kshonstocks Nov. 25 at 3:49 PM

keep an eye on $BLRX its getting volume 50-Day Avg. Volume 35,500 BLRX per ibd

0 · Reply

gargoyl Nov. 25 at 3:45 PM

$BLRX my brother is here, he sees things, patterns, algorithms behind the perception of the standards, divergent moves with chaotic outcomes that only make sense in the after math. He said we pop here .. the chart can’t hold its pattern on the lower graph, it must climb to fulfill its proper course. He is 13, special, kinda like a savant. $XBI Long the 🦋

0 · Reply

DanishViking92 Nov. 25 at 2:03 PM

$BLRX will it triple by year end?

2 · Reply

Market Cap	12.75M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-31.86%
Debt to Equity Ratio	0.52

Volume	4,700
Avg Vol	25,484
Day's Range	N/A - N/A
Shares Out	4.35M
Stochastic %K	16%
Beta	1.29
Analysts	Strong Sell
Price Target	$20.33